Related Experiment Video
Updated: Mar 15, 2026
Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
Published on: October 9, 2016
Out of Nucleus: Serine 727 Phosphorylation Orchestrates Non-Canonical STAT3 Functions-Relevance to Triple-Negative
Daniele Viavattene1, Andrea Roberto Marchetti1, Nicole Schael1
1Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Turin, Via Nizza 52, 10126 Turin, Italy.
Abstract:
Signal transducer and activator of transcription 3 (STAT3) is a central oncogenic hub in several tumors including the Triple-Negative Breast Cancer (TNBC) subtype, where its constitutive activity supports proliferation, metabolic flexibility, tumor progression, immune evasion, and therapeutic resistance. Therapeutic development has largely focused on canonical STAT3 activation driven by tyrosine 705 phosphorylation (p-Y705), which enables dimerization and transcriptional programs. However, accumulating evidence indicates that phosphorylation at serine 727 (p-S727) defines a functionally distinct STAT3 axis, underpinning non-canonical activities across extranuclear compartments that include mitochondria and endoplasmic reticulum/mitochondria-associated membranes. In TNBC, p-S727 STAT3 is frequently prevalent and may sustain oncogenic signaling when p-Y705 is low or pharmacologically suppressed, contributing to metabolic rewiring, redox control, apoptosis resistance, and metastatic fitness. Here, we review the mechanistic basis and clinical correlations of STAT3 p-S727 across cancers with emphasis on TNBC, and discuss how compartmentalized STAT3 pools may integrate kinase signaling, nutrient sensing, and stress responses. We also summarize emerging therapeutic strategies that modulate p-S727-often in conjunction with p-Y705-highlighting proof-of-concept for dual targeting or specific p-S727 to overcome limitations of Y705-centric approaches. Finally, we propose that integrating p-S727/p-Y705 distribution and activity into patient stratification could improve the efficacy-toxicity balance of STAT3-directed therapies in TNBC.
Insights
Signal transducer and activator of transcription 3 (STAT3) phosphorylation at serine 727 (p-S727) drives non-canonical oncogenic functions in Triple-Negative Breast Cancer (TNBC). Targeting p-S727 offers new therapeutic avenues beyond traditional p-Y705 inhibition.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Signal transducer and activator of transcription 3 (STAT3) is a key oncogenic driver in Triple-Negative Breast Cancer (TNBC).
- Canonical STAT3 activation involves tyrosine 705 phosphorylation (p-Y705), crucial for proliferation and tumor progression.
- Non-canonical STAT3 activity, mediated by serine 727 phosphorylation (p-S727), plays a significant role in extranuclear functions and therapeutic resistance.
Purpose of the Study:
- To review the mechanistic basis and clinical relevance of STAT3 p-S727 in cancers, particularly TNBC.
- To explore the role of compartmentalized STAT3 pools in integrating cellular signaling pathways.
- To discuss emerging therapeutic strategies targeting STAT3 p-S727, alone or in combination with p-Y705.
Main Methods:
- Literature review and synthesis of existing research on STAT3 phosphorylation.
- Analysis of mechanistic studies on STAT3's role in mitochondria and ER/mitochondria-associated membranes.
- Examination of clinical data correlating STAT3 p-S727 levels with cancer progression and treatment outcomes.
Main Results:
- STAT3 p-S727 is frequently elevated in TNBC and supports oncogenic signaling, metabolic flexibility, and resistance to therapy, especially when p-Y705 is suppressed.
- p-S727 STAT3 regulates non-canonical functions in extranuclear compartments, influencing redox control and apoptosis resistance.
- Emerging therapies targeting p-S727, or dual targeting of p-S727/p-Y705, show promise in overcoming limitations of current Y705-centric approaches.
Conclusions:
- STAT3 p-S727 represents a critical oncogenic axis in TNBC, distinct from canonical p-Y705 signaling.
- Targeting STAT3 p-S727 offers a promising strategy for overcoming therapeutic resistance in TNBC.
- Integrating p-S727/p-Y705 status into patient stratification may enhance the efficacy and safety of STAT3-directed therapies.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
01:20The JAK-STAT Signaling Pathway
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:22Amplifying Signals via Enzymatic Cascade
01:02Phosphorylation
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...